2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 194

Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data
Abstract Number: 195

The Clinical Characteristics of Patients with Inflammatory Arthritis and a Persistently Low Alkaline Phosphatase Level in a Veteran Affairs Rheumatology Clinic
Abstract Number: 196

Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Abstract Number: 197

The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application
Abstract Number: 198

Assessing Care Quality in Rheumatology Services
Abstract Number: 199

Obesity and Incident Opioid Use in Rheumatoid Arthritis
Abstract Number: 200

A Validated Text-mining Algorithm to Extract Rheumatoid Arthritis Medication Contained in Format-free Fields of Electronic Medical Records
Abstract Number: 201

Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies
Abstract Number: 202

Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies
Abstract Number: 203

Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures
Abstract Number: 204

Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Abstract Number: 205

Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis
Abstract Number: 206

Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study
Abstract Number: 207

Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice
Abstract Number: 208

Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.